The project
The project is about Understanding which treatment outcomes are most important to patients, such as improving survival, improving symptoms, less toxicity.
What are you going to do?
The potential participant will be invited to take part in one teleconference interview, up to 60 minutes. Participants will be compensated FMV. participants will be asked if they were to pick a treatment what outcomes would be the most important and their perspective on Radioligand Therapy RLT
Why is this research important?
This study is important to understand what treatment outcomes matter most to patients that go beyond traditional outcome such overall survival, the findings from this study could support with defining endpoints in clinical trials to ensure the endpoints are relevant to patients and are of actual importance
No scientific background or prior experience is needed to take part in this opportunity.
How do I get involved?
Participants eligible for inclusion in this study must meet all the following inclusion criteria:
• Signed informed consent must be obtained prior to participation in the study
Confirmed diagnosis of one of the following:
• Locally advanced, unresectable PDAC
• First-line (1L) metastatic PDAC
• Second-line or later (2L+) metastatic PDAC.
Next steps
If you are interested in joining the study or would like more information, please email Selin (selin.yurdakul@iqvia.com) quoting the involvement reference ‘ PCUK RIN Participation’.
